NLS pharma-clinical-trial-box

Cantargia has reported new data providing further insights to the mechanisms underlying the antitumor activity of the IL1RAP-binding antibody nadunolimab (CAN04). In a model of the pancreatic cancer (PDAC) microenvironment, nadunolimab potently reduced levels of various tumor-promoting molecules, in sharp contrast to an anti-IL-1β antibody which showed no such effects, reports the company in a […]

Gesynta Pharma has announced the decision to advance the development of its clinical-stage drug candidate GS-248 in endometriosis. This strategically important decision follows a recent preclinical proof-of-concept study with GS-248 in an advanced model of endometriosis, where disease-modifying properties of the drug candidate were firmly established, states the company in a press release. These data […]

Ultimovacs has announced that the first patient has been randomized in the LUNGVAC study. The study in non-small cell lung cancer (NSCLC) is the fifth Phase II clinical trial in which the universal cancer vaccine, UV1, is being investigated in combination with checkpoint inhibitors. The LUNGVAC study is designed to assess the impact of UV1 […]

BerGenBio has announced the initiation of a trial evaluating bemcentinib in combination with the current standard of care, checkpoint inhibitor pembrolizumab and doublet chemotherapy, for the treatment of 1st line Non-Small Cell Lung Cancer patients harboring STK11 mutations. “Real-world data continues to reinforce that the presence of STK11m currently result in particularly poor outcomes for […]

TILT Biotherapeutics has announced that the first US patient has been dosed in its ovarian cancer trial, using its oncolytic adenovirus, TILT-123. This open-label, phase I, dose-escalation, multicenter, and multinational, clinical trial of TILT-123 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), is for platinum resistant or refractory ovarian cancer (PROTA, also called TILT-T563). The […]

Orexo has announced positive results from the first explorative human clinical study for its nasal epinephrine (adrenaline) rescue medication for allergic reactions, OX640. The study was a comparative bioavailability study performed in 40 healthy volunteers assessing four investigational formulations of OX640 compared to a marketed epinephrine auto-injector. “The study results are truly exciting, and I […]